Medtronic plc (NYSE:MDT) Q1 2025 Earnings Conference Call
August 20, 2024 8:00 AM ET
Company Participants:
Ryan Weispfenning – VP and Head, IR
Geoff Martha – Chairman and CEO
Gary Corona – Interim Chief Financial Officer
Brad Welnick – VP, IR
Que Dallara – EVP and President, Diabetes Operating Unit
Sean Salmon – EVP and President, Cardiovascular Portfolio
Mike Marinaro – EVP and President, Medical Surgical Portfolio and Surgical Operating Unit
Conference Call Participants:
Vijay Kumar – Evercore ISI
Robert Marcus – JPMorgan
Travis Steed – Bank of America Securities
Danielle Antalffy – UBS Securities
Lawrence Biegelsen – Wells Fargo
David Rescott – Baird Equity Research
Matt Taylor – Jefferies
David Roman – Goldman Sachs
Jayson Bedford – Raymond James
Joanne Wuensch – Citi
Matt Miksic – Barclays
Patrick Wood – Morgan Stanley
Ryan Weispfenning: Good morning and welcome to another Medtronic Earnings Day. I’m Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations, and I appreciate that you’re joining us this morning for our Fiscal 2025 First Quarter Video Earnings Webcast.
Medtronic has long been a leader in the medical technology industry, with a strong focus on improving the lives of patients around the world. As we discuss our Q1 2025 earnings, it’s important to highlight the innovative products and solutions that are driving our success. From our Diabetes Operating Unit to our Cardiovascular and Medical Surgical Portfolios, Medtronic remains committed to delivering high-quality healthcare options.
During the conference call, our executive team shared insights on financial performance, strategic initiatives, and market trends. The discussion with conference call participants further emphasized the value and impact of Medtronic’s work in the healthcare sector. With a strong leadership team in place, including Chairman and CEO Geoff Martha, we are well-positioned for continued growth and success.
As we look ahead to the future, Medtronic remains dedicated to advancing medical technology and improving patient outcomes. Our ongoing commitment to innovation and excellence sets us apart in the industry, and we are confident in our ability to drive positive change in healthcare.
Impact on Me:
As a consumer of healthcare services, the success of Medtronic in delivering innovative medical technologies can directly impact my own health and well-being. By staying at the forefront of industry advancements, Medtronic’s products may offer improved treatment options and outcomes for a range of health conditions.
Impact on the World:
Medtronic’s continued success in the healthcare industry has the potential to benefit individuals and communities around the world. By providing access to advanced medical technologies and solutions, Medtronic plays a key role in improving global health outcomes and driving progress in healthcare innovation.
Conclusion:
Medtronic’s Q1 2025 earnings conference call highlighted the company’s commitment to innovation and excellence in the healthcare sector. With a focus on improving patient outcomes and driving positive change, Medtronic continues to lead the way in medical technology. As consumers and global citizens, we can look forward to the lasting impact of Medtronic’s work in the years to come.
